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these	 patients.	 Sofosbuvir/Ledipasvir	 (SOF/LDV)	 led	 the	 highest	 pooled	 estimate	
SVR12	proportion,	followed	by	Paritaprevir/Ritonavir/Ombitasivir/Dasabuvir	(PrOD),	
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1  | INTRODUCTION
Liver	 cirrhosis	 and	 hepatocellular	 carcinoma	 (HCC)	 secondary	 to	











SVR	 rate	at	 the	expense	of	a	 series	of	adverse	events	 (AEs)	and	












ease	 burden	 remains	 substantial	 for	 the	 time	 being,	 however,	 it	












additional guidance for clinical practice and future research.
2  | MATERIALS AND METHODS
2.1 | Literature search
We have conducted a systematic search of various electronic data‐
bases,	including	Ovid	Medline,	EMBASE,	Web	of	Science,	Cochrane	
Database,	 and	 Google	 Scholar	 for	 relevant	 studies	 published	 from	
inception	until	 July,	2018.	The	search	was	designed	and	conducted	
by	 an	 experienced	 medical	 librarian	 with	 input	 from	 the	 study	 in‐
vestigators,	 using	 controlled	 vocabulary	 supplemented	 with	 key‐
words	 (“sofosbuvir”	 OR	 “ribavirin”	 OR	 “ritonavir”	 OR	 “asunaprevir”	
OR	 “simeprevir”	 OR	 “daclatasvir”	 OR	 “ombitasvir”	 OR	 “ledipasvir”	
OR	 “velpatasvir”	OR	 “grazoprevir”	OR	 “elbasvir”	OR	 “DAA”	OR	 “di‐
rect‐acting	antivirals”	AND	“liver	transplantation”	AND	“hepatitis	C”	
OR	 “HCV”	 AND	 “Genotype	 1”	 OR	 “GT1”)	 (Supporting	 Information	
method	S1).	In	addition,	the	bibliographies	of	relevant	review	articles	




and relevant systematic reviews were manually searched.
2.2 | Inclusion and exclusion criteria
All	records	identified	through	database	searches	were	downloaded	
and duplicate records were removed. The title and abstract of re‐
maining records were screened for relevance to liver disease and 
human	subjects.	After	this	initial	screening,	the	lists	of	selected	stud‐
ies	were	cross‐checked	to	resolve	discrepancies.	Subsequently,	full	
articles were retrieved for detailed assessment.
Reports were included if they were original studies which con‐
tained	at	 least	 five	patients,	presented	effectiveness	of	 treatment	
of	second	generation	of	 interferon‐free	DAA	regimens	for	at	 least	
12	weeks	 in	 adult	 LT	 recipients	with	GT1	HCV	 recurrence.	 In	 ad‐
dition,	these	 included	studies	should	present	proportion	of	SVR12	
after	 the	end	of	 the	treatment.	We	excluded	studies	 that	enrolled	
LT	recipients	featured	coinfection	with	hepatitis	A,	B,	D,	E	virus	or	
human	 immunodeficiency	virus	 (HIV).	Besides,	 studies	without	 re‐
porting	AEs	and/or	sAEs	were	also	excluded.
2.3 | Study selection and data extraction
Two	 reviewers	 (JL	 and	 BM)	 worked	 independently	 to	 determine	
whether	 a	 study	 met	 inclusion	 criteria,	 abstracted	 information	 to	
assess	the	methodological	validity	of	each	candidate	study,	and	ex‐











The	quality	of	 included	studies	was	 rated	using	 the	 institute	of	
Health	Economics	(IHE)	quality	appraisal	checklist,	which	is	usu‐
ally	 employed	 for	 assessment	 of	 the	 quality	 of	 case	 series.	 As	
all	 of	 the	 included	 studies	 were	 single‐arm	 reports,	 an	 assess‐
ment	 tool	 for	 case	 series	 is	 more	 suitable	 than	 the	 Newcastle	
Ottawa	Scale	 (NOS).	 In	 this	20‐item	checklist,	 both	 risk	of	bias	
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and	 quality	 of	 reporting	were	 scored	 by	 yes,	 no,	 or	 partial/un‐
clear	 answers.	 Eight	 quality	 parameters	 including	 study	 objec‐
tive	(0‐1	points),	study	design	(0‐3	points),	study	population	(0‐3	





ered	 as	 having	 low,	moderate,	 high,	 and	 very	 high	 risk	 of	 bias,	




After	checking	for	consistency,	 the	Metaprop	module	 in	 the	R‐3.4.2	
statistical	 software	 package	 was	 used	 for	 the	 meta‐analysis.	 Given	
that,	the	SVR12	proportion	in	many	articles	are	close	to	100%.	So	the	
F I G U R E  1  Flow	chart	for	the	systematic	review	and	meta‐analysis	of	the	literature






Method).	 Heterogeneity	 across	 the	 included	 studies	 was	 assessed	
using	 the	 Cochran	 Q‐statistics	 and	 I2	 statistics,	 with	 I2 statistics 
25%‐50%,	50%‐75%,	and	>75%	considered	as	mild,	moderate,	and	se‐
vere	heterogeneity,	respectively.	Based	on	the	available	data,	subgroup	






Ritonavir/Ombitasivir/Dasabuvir	 (PrOD).	 Funnel	 plots	 and	 Egger	 re‐
gression test were used to assess potential publication biases.
Ethical	 approval	 or	 inform	 consent	 from	 patients	 was	 not	 re‐
quired,	 because	 our	 data	 were	 extracted	 from	 previous	 studies.	
Nevertheless,	the	included	studies	in	our	review	did	obtain	patient	
consent and each study was approved by ethics committee.
3  | RESULTS
3.1 | Literature search
Our	 search	 strategy	 identified	 2747	 articles	 for	 inclusion.	 After	
removing	 duplicate	 studies,	 2655	 studies	 were	 further	 evaluated	
for	 eligibility.	 Of	 these,	 1593	 studies	 were	 excluded,	 which	 had	
no	DAA,	HCV	GT1,	 or	 LT‐related	 items.	After	 screening	 the	 titles	
and	abstracts,	 another	950	 studies	were	excluded;	744	 studies	of	
them	 included	 ineligible	study	participants,	206	with	small	 sample	
size.	Finally,	112	studies	were	 retrieved	and	evaluated	 in	 full	 text.	
Of	those	reviewed	in	detail,	96	studies	were	excluded	due	to	dupli‐
cate	publication,	improper	study	design,	or	incomplete	information	
of	 effectiveness	 and	 tolerability.	 Eventually,	 16	 studies,	 published	
until	July	2018,	involving	885	patients	were	eligible	for	the	qualita‐
tive	and	quantitative	synthesis	as	detailed	in	Figure	1.	Based	on	the	











ical	characteristics.	Except	one	study13 that did not report patient 
ethnicity,	the	majority	of	patients	were	Caucasian,	male,	with	a	mean	
age	of	approximately	60‐year‐old,	had	GT1a	HCV	 recurrence,	 and	
received tacrolimus as part of their immunosuppressive treatment. 
Five	 different	 DAA	 combination	 protocols	 were	 described:	 SOF/
SMV	with	 or	without	 RBV	 (n	=	8)13‐20;	 SOF/LDV	 (n	=	3)21‐23;	 ASV/
SMV	(n	=	2)24,25;	DCV/SMV	with	or	without	RBV	(n	=	2)26,27;	PrOD	
(n	=	1).28	 Detailed	 baseline	 characteristics	 of	 the	 included	 studies	
are provided in Tables 1 and 2.
TA B L E  1  Baseline	characteristics	of	studies	included
Author Year Cases Study design Ethnicity (C/B/A/H/O)
Genotype 
1a (%) Male (%) Age(Years) Collaboration
Jacqueline 2016 46 Prospective 37/8/1/0/0 33	(71.7%) 34	(73.9%) 60	(49‐68) Multiple‐center‐
Robert 2016 151 Prospective 118/14/0/0/19 87	(57.6%) 112	(74.2%) 61	(46‐78) Multiple‐center
Lutchman 2016 50 Retrospective 25/0/0/16/9 32	(64.0%) 42	(84.0%0 61.3	±	7.1 Single‐center
Suraki 2015 123 Retrospective 91/12/0/12/8 74	(60.2%) 93	(75.6%) 61	±	6 Multiple‐center
Saro 2015 32 Retrospective 11/0/2/19/0 22	(68.8%) 21	(65.6%) 58	(47‐71) Single‐center
Jackson 2016 67 Retrospective ‐ 23	(34.3%) 46	(68.7%) 61.5	±	6.6 Multiple‐center
Punzalan 2015 42 Retrospective 34/1/1/6/0 33	(78.6%) 28	(66.7%) 58 Single‐center
Toru 2017 74 Retrospective 0/0/74/0/0 ‐ 32	(43.2%) 62.7	±	4.5 Multiple‐center
Kerstin 2015 6 Retrospective 6/0/0/0/0 5	(83.3%) 5	(83.3%) 58.5	(50‐63) Single‐center
Masaki 2017 9 Retrospective 0/0/9/0/0 ‐ 5	(55.6%) 64.7	±	0.85 Single‐center
Neil 2015 56 Retrospective 48/0/0/0/8 44	(78.6%) 42	(75.0%) 61 Multiple‐center
Paul 2014 34 Prospective 29/4/0/0/1 29	(85.3%) 27	(79.4%) 59.6	±	6.6 Multiple‐center
Yoshihide 2017 54 Retrospective 0/0/54/0/0 ‐ 25	(46.3%) 64	(47‐77) Multiple‐center
Mohamed 2017 60 Retrospective 53/0/0/0/7 47	(78.3%) 42	(70.0%) 59.9	±	7.25 Single‐center
Mohamed	A 2016 46 Retrospective 32/0/0/0/14 26	(56.5%) 32	(69.6%) 62.0	±	8 Multiple‐center
Xavier 2016 35 Prospective 34/0/0/0/1 ‐ 22	(62.9%) 62	(27‐69) Multiple‐center
A,	Asian;	B,	black;	C,	Causian;	H,	Hispanic;	O,	others.




Once	 DAA	 treatment	 completed,	 patients	 were	 followed	 up	 for	
evaluating	SVR12	proportion.	 In	 total,	805	out	of	885	 (91.0%)	pa‐
tients	 successfully	 achieved	 SVR12.	 The	 pooled	 estimate	 SVR12	
proportion	among	all	 LT	 recipients	were	93%	 (95%	CI:	0.89,	0.96),	






of	 37%	 (95%	CI:	 0.14,	 0.64;	 τ2	=	0.30,	P	<	0.01,	 I2	=	98%,	 Random	
effects	 model,	 Figure	 S3).	 Pooled	 estimate	 incidence	 rate	 of	 gas‐
trointestinal	AEs	was	10%	 (95%	CI:	 0.02,	0.23;	 τ2	=	0.11,	P	<	0.01,	
I2	=	96%,	Random	effects	model,	Figure	S4)	and	pooled	estimate	in‐
cidence	rate	of	skin	problems	was	7%	(95%	CI:	0.02,	0.15;	τ2	=	0.06,	


















NR ‐ SOF+SMV±RBV 12	wk 60	(0‐276)
Lutchman 96%	TAC 1 pts changed 
cyclosporin	into	TAC
6.3	±	1.2 SOF+SMV 12	wk ‐




NR 6.58 SOF+SMV 12	wk 48	(7‐166)
Jackson TAC	84%,	CsA	6%,	SIR	
6%










NR 6.3 ASV+DCV 24	wk ‐














‐ SOF+SMV±RBV 12	wk 53
Paul TAC	85%,	CsA	15%,	
MMF	32%,	PRED	6%
No	change 6.6 PrOD 12	wk ‐
Yoshihide TAC	75%,	MMF	46%,	
PRED	28%
NR 6.5 LDV+SOF 12	wk 61	(1‐158)






7.79 LDV+SOF 12/24	wk 30	(2‐117)
Xavier	2016 TAC	71%,	CsA	29% NR 6.9 SMV+DCV+RBV 24	wk 47	(14‐114)
ASV,	 Asunaprevir;	 CsA,	 Cyclosporine	 A;	 DAAs,	 direct‐acting	 antivirals;	 DCV,	 Daclatavir;	 EVR,	 Everolimus;	 LDV,	 Ledipasvir;	 m,	 months;	 MMF,	
Mycophenolate	 Mofetil;	 MPA,	 Mycophenolic	 Acid;	 PrOD,	 Paritaprevir/Ritonavir/Ombitasivir/Dasabuvir;	 Pts,	 patients;	 PRED,	 Prednisone;	 RAP,	
Rapamune;	RBV,	Ribavirin;	SIR,	Sirolimus;	STE,	Steroid;	SOF,	Sofosbuvir;	SMV,	Simeprevir;	TAC,	Tacrolimus.
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P	<	0.01,	 I2	=	93%,	 Random	 effects	 model,	 Figure	 S5).	 SAEs	 were	
mainly	associated	with	kidney	injury,	were	reported	in	45	patients,	










The	METAVIR	 Fibrosis	 Score,	 simply	 put,	 is	 a	 evaluate	 system	 to	




numerous	 septa	 without	 cirrhosis;	 F4	 stage,	 cirrhosis).	 A	 total	 of	
eight studies evaluated the levels of fibrosis and cirrhosis of pa‐
tients	according	to	METAVIR	Fibrosis	Score.	The	pooled	SVR12	rate	
estimates	among	patients	with	METAVIR	Fibrosis	Score	 for	F0‐F2	











TA B L E  3   Incidence	of	adverse	events	and	serious	adverse	events	during	direct‐acting	antivirals	treatment	for	patients	of	hepatitis	C	virus	 
genotype 1 recurrence post liver transplantation
Jacqueline 
2016 Robert 2016 Lutchman 2016 Suraki 2015 Saro 2015 Jackson 2016
Punzalan  








Nausea 23.9% 11.3% 4.4% 5.0% 3.0% 11.3% 36.0% 24.0% 3.0%









Insomnia 13.0% 35.9% 2.0% 21.0% 26.0% 5.0%
Dizziness 9.0% 7.0% 18.0%
Fever 3.0%
Headache 37.0% 18.5% 8.7% 5.0% 25.0% 18.5% 36.0% 44.0% 23.0% 5.0% 14.0%




21.7% 13.9% 44.6% 6.0% 6.0% 13.9% 12.0% 35.0% 21.0% 31.0%
Anemia 10.6% 77.0% 10.6% 30.0% 29.0% 54.0%




Joint or muscle 
pain
4.4% 9.0% 2.4% 7.0% 39.0%
Others 11.9% 14.0% 21.5% 20.2% 22.2% 28.0% 42.0% 10.0%
sAEs 10.9% 11.9% 6.5% 2.4% 0 11.9% 2.4% 0 0 0 3.6% 6.0% 13.0% 0 0 23.0%
GI,	gastrointestinal;	sAEs,	serious	adverse	events.





compared	 to	 761	 recipients	without.	 The	 pooled	 estimate	 SVR12	
proportion	of	 recipients	 treated	with	RBV	was	90%	 (95%CI:	0.84,	
0.94).	 For	 recipients	 treated	 without	 RBV,	 the	 pooled	 proportion	
was	94%	(95%CI:	0.89,	0.97).	There	was	no	significant	difference	in	

















the	 unbalanced	 application	 of	DAAs	 for	GT1	HCV	 recurrence	 ex‐
ists	among	different	regions.	There	is	a	trend	that	the	first‐class	of	




Furthermore,	DAA	 availability	 has	 been	 delayed	 due	 to	 economic	
constraints and regulatory rules.31	Although	two	studies	from	Japan	
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suggested	that	DAA	treatment	is	effective	in	Asian	patients,	multire‐
gional and systematic studies should be combined to further confirm 
the	effectiveness	of	DAA	treatment	for	different	regions.
The	 average	 time	 of	 progression	 from	 initial	HCV	 infection	 to	
cirrhosis	 is	about	30	years,	but	20%‐30%	of	 liver	transplant	recipi‐
ents	develop	cirrhosis	within	5	years.32 Retransplantation is the only 
F I G U R E  2  Pooled	estimate	proportion	of	12	weeks	sustained	virologic	response	after	treatment	completion	and	95%	confidence	interval	
after	direct‐acting	antivirals	treatment	of	GT1	HCV	recurrence	post	liver	transplantation	from	16	studies.	Abbreviations:	CI,	confidence	
interval;	Events,	the	number	of	patients	who	reached	SVR12;	Total,	the	number	of	patients	analyzed
F I G U R E  3  Pooled	estimate	proportion	of	serious	adverse	events	and	95%	confidence	interval	after	direct‐acting	antivirals	of	GT1	HCV	
recurrence	post	liver	transplantation	from	16	studies.	Abbreviations:	CI,	confidence	interval;	Events,	the	number	of	patients	who	reached	
SVR12;	Total,	the	number	of	patients	analyzed
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option	 to	 achieve	 long‐term	 survival	 of	 patients	 with	 decompen‐
sated	 cirrhosis.	However,	 due	 to	 organ	 shortage	 and	 poor	 clinical	
outcome,	 retransplantation	 is	 clearly	 not	 a	 sustainable	 solution.33 
In	our	 subgroup	analysis	of	 liver	 transplant	 recipients	with	SVR12	
rate	and	fibrosis	data	(METAVIR	Fibrosis	Score),	our	detailed	analysis	
supports	 the	 latest	evidence‐based	guidelines	 that	DAAs	also	 can	
be	 effectively	 used	 in	 eradicating	HCV	 in	 patients	with	 advanced	
fibrosis	or	cirrhosis	post	LT.34	We	observed	a	higher	SVR12	pooled	





to be initiated early after transplantation.
Five	different	combinations	of	DAA	treatment	were	identified	in	




pooled	 estimate	 SVR12	 proportion	 of	 90%,	 which	 is	 comparable	
with	 a	 recent	 study	 reporting	 SVR12	 rate	 of	 88%.30	 A	 number	 of	
studies	have	pointed	out	that	SMV	may	interact	with	Cyclosporine	
A	(CsA),	and	therefore	the	immunosuppressant	tacrolimus	is	recom‐











proportion	 of	 97%.	Unfortunately,	 PrOD	 is	 contraindicated	 in	 pa‐
tients	with	cirrhosis	and	has	a	potential	to	increase	the	plasma	CsA	
levels	by	five	to	six	folds	and	tacrolimus	levels	by	60‐85	folds,	which	
limited its clinical application.28	In	addition,	efficacy	and	safety	were	
not	established	for	shorter	duration	therapy,	or	more	advanced	fi‐
brosis/cirrhosis	in	a	real	world	setting.	Combination	of	ASV	and	DCV	
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were administered by two Japanese studies with the lowest pooled 
estimate	SVR12	proportion	of	81%.	Although	this	combination	had	a	
cost‐effective	advantage,	increased	transaminase	levels	were	com‐




and	prolonged	 treatment	period	of	24	weeks	 in	 these	 two	studies	
should be noted.




action.39,40	What	 is	 clear,	 however,	 is	 adverse	 effects.	Hemolytic	
anemia has been observed in about one third of the patients. 
Lymphopenias,	pruritus,	and	rash	also	commonly	occur.	Thus,	pa‐
tients	 treated	with	RBV	often	 need	 a	 close	monitoring	 and	dose	
adjustment,	especially	for	those	with	chronic	kidney	disease.	 It	 is	
also	recommended	that	patients	treated	with	RBV	should	undergo	
at	 least	6‐month	washout	period	due	 to	 the	possible	 teratogenic	
and embryocidal effects.40‐42	In	current	study,	we	observed	an	in‐
creased	pooled	estimate	incidence	rate	of	sAEs	in	patients	treated	
with	 RBV,	 in	 accordance	 with	 the	 results	 from	 previous	 studies.	
Given	 that	 a	 number	 of	 studies	 have	 pointed	 out	 RBV	were	 not	
correlated	with	an	increased	SVR12	rate,13,16,20,43 we compared pa‐
tients	treated	or	not	treated	with	this	medication.	Our	results	also	
indicated	 that	 RBV	was	 not	 correlated	with	 an	 increased	 pooled	
estimate	 SVR12	 proportion.	We	 also	 assessed	 the	 tolerability	 of	
DAA	 treatment	 by	 analyzing	 pooled	 estimate	 proportion	 of	 AEs	
and	sAEs.	General	symptoms,	gastrointestinal	symptoms,	and	skin	








function commonly occurred in liver transplant recipients with 
the	prevalence	ranging	from	17%	to	95%.44,45	Approximately	40%	
of	 these	 patients	 had	 already	 experienced	 a	 hepatorenal	 syn‐
drome pretransplantation.46	In	addition,	toxic	reasons,	ischemia	
reperfusion	and	Calcineurin	Inhibitor	(CNI)‐associated	nephrop‐










higher compared to normal renal function when dosed 1 hour 
before	 or	 1	hour	 after	 hemodialysis,	 respectively.50	 However,	
there	are	conflicting	data	about	the	application	of	SOF	in	clinical	




cohort	 study	 enrolled	 50	 patients	 with	 Glomerular	 Filtration	
Rate	 (GFR)	<35	mL/min	per	1.73	m2	 for	 treatment	with	 a	 SOF‐
based	therapy.	All	genotypes	were	included	and	more	than	half	
of them were cirrhotic patients. The results indicated that there 
is	 no	 significant	 change	 in	 GFR	 for	 patients	 who	 were	 not	 on	
dialysis.52	More	recently,	Teegen	et	al	49 also documented that a 
dose	reduction	for	SOF	did	not	seem	to	be	necessary	to	prevent	
further	 renal	 damage.	 Thus,	 additional	 data	 are	 still	 needed	 to	
further	assess	the	safety	of	SOF	in	transplant	recipients.
CNIs	are	the	backbone	of	 immunosuppressive	treatment	of	LT.	
Eighty	percent	of	 liver	 transplant	 recipients	were	using	 tacrolimus	
alone or in combination with mycophenolate 1 year post transplan‐
tation.53	Although	CNIs	can	reduce	the	incidence	of	acute	injection	
and	 improve	 overall	 survival,	 they	 are	 inevitably	 associated	 with	











erability	of	DAA	 treatment.	Thus,	 a	 control	 group	 is	not	 included,	
such	 as	 patients	 treated	with	DAAs	 before	 LT	 or	 treated	with	 in‐
terferon	post	LT.	Thus,	without	such	a	control,	we	cannot	conclude	
whether	treatment	post	LT	has	any	advantage	than	treatment	prior	
to	 LT	 or	 interferon‐treated	 recipients.	 Besides,	most	 studies	were	
from	 developed	 regions,	 including	 North	 American	 or	 European	
countries.	Hence,	multiregional	studies	are	still	needed	to	substan‐
tiate the comprehensive information for better clinical guidance 
globally.	Finally,	 the	field	of	HCV	treatment	 is	a	dynamic	and	con‐
stantly	changing	landscape.	A	number	of	new	agents	or	combination	
approaches may still in clinical trials or just licensed.





stage of the patients and regional/social factors.
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